|
|
Upfront Briefing
Definium’s LSD pill has now cleared two Phase 3 trials in two months, this time in generalized anxiety, with an effect size that had Jefferies and Stifel reaching for superlatives before the coffee went cold. Psychedelics spent a decade as a punchline. They are now a filing timeline. Sangamo’s estate held an auction and PTC walked off with the Fabry gene therapy for $111M, outbidding the stalking horse that thought it had the lot locked in June; Lilly took the platforms for $50M. Meanwhile Prader-Willi had its worst session in months — seven deaths logged next to Neurocrine’s Vykat XR, and Aardvark confirming its Phase 3 is not coming back.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,748.5 |
0.3% |
13.0% |
| Nasdaq 100 |
29,742.6 |
0.7% |
18.0% |
| Russell 2000 |
3,045.5 |
0.6% |
21.4% |
| Healthcare (XLV) |
168.4 |
0.3% |
8.3% |
| Biotech (XBI) |
159.4 |
0.8% |
31.2% |
| Nasdaq Biotech (NBI) |
6,878.9 |
0.4% |
20.5% |
| Clinical Trials (BBC) |
53.1 |
1.4% |
41.0% |
|
- Biotech outperformed with XBI up 0.8% against the S&P 500's 0.3%, led by Definium's double-digit move on the Voyage Phase 3 readout in generalized anxiety disorder and PTC's auction win for Sangamo's Fabry gene therapy.
- July CPI landed at 3.4% annual and 0.1% on the month on 12 August, matching consensus and pushing September Fed hike odds back below 50%, while CoreWeave and Super Micro results carried the Nasdaq 100 to a one-month high.
- Market data: U.S. cash close Wednesday, 12 August 2026.
The Big 3
|
1
|
Definium’s LSD pill clears a second Phase 3, this time in anxiety
|
- Definium's single-dose oral LSD candidate DT120 met its primary and all key secondary endpoints in Voyage, the first of two Phase 3 trials in generalized anxiety disorder.
- Why it matters: Voyage randomised 214 adults and returned a 5.4-point placebo-adjusted HAM-A improvement at week 12 — minus 11.6 versus minus 6.2, p<0.0001, Cohen's d 0.81 — off a single dose. GAD effect sizes do not usually look like that, which is why Jefferies and Stifel both marked it above expectations and DFTX moved double digits. DT120 already carries Breakthrough Therapy designation here and a positive MDD Phase 3 from June, so the psychedelics-as-real-pharma question becomes a filing question. Evercore models $2B peak in GAD alone. Risk: Panorama, the confirmatory Phase 3, reads out in September, and a miss there pushes the NDA past 1H 2027 and re-prices the entire complex.
- Source: STAT
- More: Endpoints; BioPharma Dive
|
|
2
|
PTC outbids Astellas for Sangamo’s BLA-stage Fabry gene therapy
|
- PTC was named winning bidder for ST-920, a one-time AAV gene therapy for Fabry disease, in Sangamo's court-supervised Chapter 11 auction — $111M cash at closing plus up to $100M in approval milestones.
- Why it matters: PTC pays $111M cash at closing plus up to $100M tied to FDA approvals — $80M on accelerated, $20M on full — for an asset whose rolling BLA completes in Q4. The seller is Sangamo, in Chapter 11 since June, and PTC outbid Astellas, the stalking horse that anchored the Fabry lot. That is the read: a Section 363 auction cleared a near-registration gene therapy for roughly a tenth of what a solvent counterparty would have paid. PTC brings rare-disease commercial reach, not a Fabry franchise, so the launch build is still ahead of it. Risk: the sale needs court approval, and accelerated approval rests on eGFR slope from a 32-patient Phase 1/2.
- Source: PR Newswire
|
|
3
|
Prader-Willi’s two lead assets take hits in a single session
|
- Prader-Willi advocacy groups alerted clinicians to seven deaths and more than 100 serious adverse events logged against Neurocrine's Vykat XR, and Aardvark confirmed it will not restart its terminated Phase 3 of ARD-101 as designed.
- Why it matters: Two blows to the same indication in one session. The Vykat reports sit in FAERS as of 31 July, surfaced by the Foundation for Prader-Willi Research and IPWSO rather than by FDA; causality is unestablished, baseline PWS mortality runs 1—3% annually, and the groups asked for informed prescribing rather than withdrawal — which is why NBIX gave back only a few percent. Aardvark walking away from HERO removes the nearest challenger, so Vykat's competitive position improves as its safety narrative worsens. Neurocrine paid $2.9B for Soleno and booked $54M in stub-period Q2 sales against a $94M pro-forma run rate. BMO's read: prescriber caution constrains the launch curve.
- Source: STAT
- More: Endpoints; Fierce Biotech
|
Everything Else that broke
- Lilly filed six lawsuits targeting an alleged retatrutide black market ahead of an approval filing. — Fierce Pharma
- Talphera said its NEPHRO CRRT study of nafamostat is 75% enrolled and on track to finish this year. — PR
- FDA and industry outlined GDUFA IV with new onshoring incentives for 2028-2032 generic-drug reviews. — Endpoints
- Vaccine makers pushed back on splitting MMR, calling the idea theoretically possible but practically far-fetched. — Endpoints
- Legend posted its first profit, but Carvykti now faces rising pressure from T-cell engagers and Gilead's autologous CAR-T. — Fierce Pharma
- ArkBio won China IND clearance for AK0406, a long-acting antiviral drug-Fc conjugate for influenza prophylaxis. — PR
- Lilly won Sangamo's capsid delivery, zinc finger and MINT platforms plus prion program ST-506 for $50M cash, with closing set for on or about 4 September. — Sangamo release
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
PTC won BLA-stage ST-920 for Fabry disease out of Sangamo's Chapter 11 auction — $111M cash plus up to $100M in milestones (see The Big 3). — PR Newswire
- Lilly won Sangamo's capsid, zinc finger and MINT platforms plus prion program ST-506 for $50M cash at closing. — Sangamo release
VC / Private Financings
- InduPro closed a $77M Series B led by The Column Group, joined by Vida Ventures, Solasta Ventures, Sanofi and Eli Lilly, and dosed the first patient in Phase 1 for EGFR-targeted bispecific ADC IDP-001. — Endpoints
IPOs / Follow-Ons
- No notable IPOs or follow-ons surfaced within the last 24 hours.
Academic Corner - Mechanistic machine learning improved prediction of prime-editing outcomes in OptiPrime. — Nature Biotech
- Ivonescimab plus chemotherapy posted encouraging preliminary response rates in first-line triple-negative breast cancer. — Nature Medicine
|
|
A psychedelic that keeps landing, a fire sale with two buyers, and a corner of rare disease having its worst day in months.
— BioBucks Team
|
|
|
